High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: First results of a randomized trial

Journal of Clinical Oncology

Volumn 22, Issue 12, 2004, Pages 2273-2283

  Zander, A R ^a   Kroger N ^a   Schmoor, C ^a   Kruger W ^a   Mobus V ^a   Frickhofen, N ^a   Metzner, B ^a   Schultze, W ^a   Berdel, W E ^a   Koenigsmann, M ^a   Thiel, E ^a   Wandt, H ^a   Possinger, K ^a   Trumper L ^a   Kreienberg, R ^a   Carstensen, M ^a   Schmidt, E H ^a   Janicke F ^a   Schumacher, M ^a   Jonat, W ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MITOXANTRONE; THIOTEPA;

ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG MEGADOSE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SAMPLE SIZE; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ADULT; AUTOTRANSPLANTATION; BREAST TUMOR; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PROGNOSIS; SURVIVAL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 2942744745     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.07.026     Document Type: Article

References (44)

1. Peters WP: The rationale for high-dose chemotherapy with autologous bone marrow support in treating breast cancer, in Dicke K, Spitzer G, Zander A (eds): Autologous Bone Marrow Transplantation. Proceedings on the First International Symposium. Houston, TX, AM Anderson Cancer Center Press, 1985, pp 189-196
2. Frei E III, Antman K, Teicher B, et al: Bone marrow autotransplantation for solid tumors: Prospects. J Clin Oncol 7:515-526, 1989
3. Antman K, Bearman SI, Davidson N, et al: Doise intensive strategy in breast cancer: Current status, in Champlin RE, Gale RP (eds): New Strategies in Bone Marrow Transplantation. New York, NY, Allen R. Liss, 1991, pp 423-436
4. Hryniuk W, Levine MN: Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4:1162-1170, 1986
5. Hryniuk W, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281-1288, 1986
6. Jones SE, Moon TE, Bonadonna G, et al: Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base. Am J Clin Oncol 10:387-395, 1987
7. Moon TE, Jones SE, Bonadonna G, et al: Development and use of a natural history data base of breast cancer studies. Am J Clin Oncol 10:396-403, 1987
8. Abeloff MD, Beveridge RA, Donehower RC, et al: Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer. J Natl Cancer Inst 82:570-574, 1990
9. Davidson NE, Abeloff MD: Adjuvant systemic therapy in women with early-stage breast cancer at high risk for relapse. J Natl Cancer Inst 84:301-305, 1992
10. Kaufmann M, Jonat W, Caffier H, et al: Adjuvant systemic risk adapted cytotoxic ± tamoxifen therapy in women with node positive breast cancer, in Salmon S (ed): Adjuvant Therapy of Cancer. Orlando, FL, V. Grune and Stratton, 1987, pp 337-346
11. Clark GM, McGuire WL: New biologic prognostic factors in breast cancer. Oncology 3:49-54, 1989
12. Buzzoni R, Bonadonna G, Valagussa P, et al: Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol 9:2134-2140, 1991
13. Bonadonna G, Zambetti M, Valagussa P: Sequential or alternating doxorubicin and CMF regimes in breast cancer with more than three positive nodes: Ten years results. JAMA 273: 542-547, 1995
14. Buzdar AV, Kau S-W, Hortobagyi GN, et al: Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. Cancer 69:448-452, 1992
15. Peters WP, Ross M, Vredenburgh JJ, et al: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11:1132-1143, 1993
16. Peters WP, Berry D, Vredenburgh JJ, et al: Five year follow-up of high-dose combination alkalyting agents with ABMT as consolidation after standard-dose CAF for primary breast cancer involving 10 axillary lymph nodes (Duke/CALGB 8782). Proc Am Soc Clin Oncol 14:317, 1995 (abstr 933)
17. Gianni AM, Siena S, Bregni M, et al: Efficiacy, toxicity and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary lymph nodes: Five-year results. J Clin Oncol 15:2312-2321, 1997
18. Eddy D: High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. J Clin Oncol 10:657-670, 1992
19. Gradishar WJ, Tallman MS, Abrams JS: High-dose chemotherapy for breast cancer. Ann Intern Med 125:599-604, 1996
20. Peters WP, Rosner G, Vredenburgh J, et al: A prospective, randomized comparison of two doses of combination alkalyting agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): Preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Proc Am Soc Clin Oncol 18:1a, 1999 (abstr 3)
21. Rodenhuis S, Richel DJ, van der Wall E, et al: A randomized trial of high-dose chemotherapy and hematopoietic progenitor cell support in operable breast cancer with extensive axillary lymph node involvement. Lancet 352:515-521, 1998
22. Hortobagyi GN, Buzdar AU, Theriault RL, et al: Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 92:225-233, 2000
23. The Scandinavian Breast Cancer Study 9401. Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy. Proc Am Soc Clin Oncol 18:2a, 1999 (abstr 6)
24. Bezwoda WR. Randomized, controlled trial of high-dose chemotherapy (HD-CNVp) vs. standard dose (CAF) chemotherapy for high risk, surgically treated, primary breast cancer. Proc Am Soc Clin Oncol 18:2a, 1999 (abstr 8)
25. Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 13:2483-2489, 1995
26. Damon LE, Wolf JL, Rugo HS, et al: High-dose chemotherapy (CTM) for breast cancer. Bone Marrow Transplant 26:257-268, 2000
27. SAS Institute Inc: SAS Language, Version 6. Cary, NC, 1990
28. Kalbfleisch JD. Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY Wiley, 1980
29. Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457-181, 1958
30. Cox DR: Regression models and life table (with discussion). J R Stat Soc B 34:187-220, 1972
31. Schmoor C, Sauerbrei W, Bastert G, et al: Long term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF. Eur J Cancer 37:1123-1131, 2001
32. Bearman SI, Appelbaum FR, Buckner CD, et al: Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6:1562-1568, 1988
33. Rodenhuis S: The status of high-dose chemotherapy in breast cancer. Oncologist 5:369-375, 2000
34. Gianni A, Bonadonna G: Five year results of the randomized clinical trial comparing standard versus high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with >3 positive lymph nodes. Proc Am Soc Clin Oncol 20:80, 2001
35. Crown JP, Lind M, Gould A, et al: High-dose chemotherapy (HDC) with autograft (PBP) support is not superior to cyclophosphamide (CPA), methotrexate and 5-FU (CMF) following doxorubicin (D) induction in patients (pts) with breast cancer and 4 or more involved axillary lymph nodes (4+ LN): The Anglo-Celtic I study. Proc Am Soc Clin Oncol 21:42a, 2002 (abstr 166)
36. Roche H, Pouillard P, Meyer N, et al: Adjuvant high-dose improves early outcome for high-risk (N>7) breast cancer patients: The Pegase-01 trial. Proc Am Soc Clin Oncol 20:25a, 2000 (abstr 102)
37. Rodenhuis S, Bontenbal M, Beex L, et al: Randomized phase III study of high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin in operable breast cancer with 4 or more axillary lymph nodes. Proc Am Soc Clin Oncol 19:71a, 2002 (abstr 286)
38. Peto R, Boreham J, Clarke M, et al: UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355:18-22, 2000
39. Bergh J, Wiklund T, Erikstein B, et al: Tailored fluorouracil, epirubicin and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial - Scandinavian Breast Cancer Group 9401 study. Lancet 356:1384-1391, 2000
40. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
41. Attal M, Harousseau JL, Stoppa AM, et al: A prospective, randomised trail of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du My élome. N Engl J Med 335:91-97, 1996
42. Rodenhuis S, Bontenbal M, Beex LV, et al: High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer: Netherlands Working Party on Autologous Transplantation Solid Tumors. N Engl J Med 349:7-16, 2003
43. Tallman MS, Gray R, Robert NJ, et al: Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 349:17-26, 2003
44. Elfenbein GF: Stem-Cell Transplantation for high-risk breast cancer. N Engl J Med 3:80-82, 2000